NCT05799820

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

An Open-label, Multicenter Phase II Study of QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, muticenter phase II study to evaluate the efficacy and safety of QL1706 monotherapy or in combination with bevacizumab and XELOX as first-line treatment of unresectable advanced or metastatic CRC.

Conditions

• Colorectal Carcinoma

Interventions

Type	Name	Description
DRUG	QL1706	5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
DRUG	Bevacizumab	7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
DRUG	Oxaliplatin injection	130mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
DRUG	Capecitabine	1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

Timeline

• Start date: 2022-09-29
• Primary completion: 2024-03-30
• Completion: 2025-09-30
• First posted: 2023-04-05
• Last updated: 2023-05-25

Locations

1 site across 1 country: China